9 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's
3imrg2gd8vm8ngg aa24nv7rn2szy8r7hf5sg35raymod8s5o5
RYTM
29 Apr 24
, Department of Pediatrics, University of Washington. "In this first study to investigate the use of setmelanotide as a targeted treatment
5e4c34rniam9k0gop6yv91vngmglbzzkc4eki
RYTM
29 Apr 24
and Division of Endocrinology, Department of Pediatrics, University of Washington. "In this first study to investigate the use of setmelanotide as a targeted
upy7z1v00mw6vlzd7ralo3r5n9iy7i96y32sytopa87mhe2crze492ky
RYTM
24 Apr 24
clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical
9x1xp5uozupiyvek6h46mmzaz1 y9
RYTM
16 Apr 24
development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small
- Prev
- 1
- Next